Marshall University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Marshall University sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 3 currently recruiting 6 completed early-phase tilt top decile by trial count

Marshall University: 12 sponsored US clinical trials, 3 recruiting.

Marshall University sponsors 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fat Embolism Syndrome, with 1 trials.

Top-decile sponsor footprint

Marshall University ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING

Return to Play After ACL Reconstruction With Bone Marrow Aspirate, DBM, and an Internal Brace

NCT06294314
RECRUITING NA

Outcomes of the Nanoscopic Partial Meniscectomy Versus Standard Arthroscopic Partial Meniscectomy

NCT05617807
RECRUITING

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
ACTIVE NOT RECRUITING NA

Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations

NCT02336217
COMPLETED NA

Biofeedback Training Targeting at Knee Proprioception

NCT07691528
TERMINATED Phase 2

Treatment of Elevated Blood Pressures in Early Pregnancy

NCT05955040
COMPLETED NA

Prevention of Broncho-aspiration (BA) in Adult Subjects During Their ICU Stay

NCT05284084
COMPLETED NA

Brief Physical Activity Program to Increase Physical Fitness in Elementary School Children

NCT02087774
COMPLETED

Chemotherapy Resistance and Sensitivity Testing in Lung Tumors

NCT01570855
TERMINATED Phase 2

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

NCT00899353
COMPLETED

Compliance With American Diabetes Association Treatment Guidelines for Adult Ketoacidosis

NCT00589680
COMPLETED

Incidence of Fat Embolism With Computer Assisted Total Knee Arthroplasty

NCT00656877

Phase Distribution

PhaseTrial count
Phase 2 2

Therapeutic Areas

Fat Embolism Syndrome 1
Anterior Cruciate Ligament Rupture 1
Cardiac Output, High 1
Cardiac Output, Low 1
Diastolic Hypertension 1
Systolic Hypertension 1
Diabetes Mellitus 1
Childhood Obesity 1
Meniscus Tear 1
Pregnancy Related 1

What is open in the Marshall University pipeline

3 recruiting of 12 indexed (25% open); 6 completed (50%).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Fat Embolism Syndrome (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Marshall University: open-pipeline peers nationwide

Peers matched on 12 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Marshall University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 2468101214 0%10%20%30% Total trials Recruiting share Marshall UniversityAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAB ScienceAbbott Point of CareAbdul Latif Jameel Poverty Action LabAccutar Biotechnology
Marshall University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Marshall University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Marshall University page

12 registered trials is a research-attention snapshot, not an endorsement of Marshall University or any single study.

  • 3 of Marshall University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Fat Embolism Syndrome is the condition Marshall University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fat Embolism Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Marshall University pipeline card: 12 registered trials from official public datasets.Report a data error.